Bristol Myers Squibb has received the FDA nod for its potential-blockbuster heart disease drug.
The agency’s decision was revealed last week, giving BMS approval to use the drug, Camzyos, to treat obstructive hypertrophic cardiomyopathy (obstructive HCM) in adults. Camzyos is the first and only FDA-approved cardiac myosin inhibitor that specifically targets the source of obstructive HCM.
When BMS acquired MyoKardia for $13.1 billion back in 2020, the drug was a crucial factor. BMS has been going for the heart lately, and Camzyos is only one of a few launches that the company is (literally) banking on. Combined, the company expects these upcoming drugs to have peak sales of more than $4 billion.
“This approval builds on decades of cardiovascular leadership and reflects our steadfast commitment to people impacted by cardiovascular disease,” said Samit Hirawat, executive vice president and chief medical officer at BMS.
